Is Novavax (NVAX) Stock a Buy After FDA Decision?

  • Novavax (NVAX) stock is on the move after getting Covid-19 vaccine approval.
  • However, it comes alongside a warning about the vaccine from overseas.
  • This has resulted in heavy trading of NVAX shares moving its price up and down today.
NVAX Stock - Is Novavax (NVAX) Stock a Buy After FDA Decision?

Source: cortex-film /

Novavax (NASDAQ:NVAX) stock is in the spotlight on Friday as investors react to recent news concerning its Covid-19 vaccine.

First off, Novavax finally got the U.S. Food and Drug Administration (FDA) approval for its Covid-19 vaccine that it’s been seeking for so long. This allows for the use of the vaccine in American adults.

Unfortunately for NVAX stock, that announcement also came alongside bad news from across the sea. The European Union’s European Medicines Agency (EMA) listed a “severe allergic reactions” warning as a possible side effect of the vaccine.

As if that wasn’t bad enough, the EMA listed another potential side effect for Novavax’s Covid-19 vaccine. That covers “unusual or decreased feeling in the skin.” All in all, this pulled NVAX shares down from a rally early this morning.

Now the real question investors have is if NVAX stock is still worth buying. Let’s check out the latest analysts’ opinions on that below!

Is NVAX Stock Worth Buying?

NVAX started off strong this morning before quickly falling below yesterday’s close. As of Friday afternoon, the stock is up 1.7% alongside heavy trading.

Investors seeking out more of the latest stock market news will want to stick around!

InvestorPlace is home to all of the most recent stock news traders need to know about for Friday! Among that is what’s happening with shares of Plug Power (NASDAQ:PLUG) and DraftKings (NASDAQ:DKNG), as well as the latest housing market situation. You can find all of that at the following links!

More Friday Stock Market News

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines.

Article printed from InvestorPlace Media,

©2024 InvestorPlace Media, LLC